Modality
Peptide
MOA
CD47i
Target
IL-17A
Pathway
Proteasome
CTCLAsthma
Development Pipeline
Preclinical
~Dec 2018
→ ~Mar 2020
Phase 1
Jun 2020
→ Jan 2028
Phase 1Current
NCT05044866
1,359 pts·CTCL
2024-09→2028-01·Recruiting
NCT03226467
1,559 pts·CTCL
2020-06→2025-08·Active
2,918 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-08-237mo agoPh2 Data· CTCL
2028-01-221.8y awayPh2 Data· CTCL
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
P1/2
Active
P1/2
Recruit…
Catalysts
Ph2 Data
2025-08-23 · 7mo ago
CTCL
Ph2 Data
2028-01-22 · 1.8y away
CTCL
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05044866 | Phase 1/2 | CTCL | Recruiting | 1359 | ACR20 |
| NCT03226467 | Phase 1/2 | CTCL | Active | 1559 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A |